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Verapamil reverses PTH- or CRF-induced abnormal fatty acids oxida-
lion in muscle. Chronic renal failure (CRF) is associated with impaired
long chain fatty acids (LCFA) oxidation by skeletal muscle mitochon-
dna. This is due to reduced activity of carnitine palmitoyl transferase
(CPT). These derangements were attributed to the secondary hyper-
parathyroidism of CRF, since prior parathyroidectomy in CRF rats
reversed these abnormalities and PTH administration to normal rats
reproduced them. It was proposed that these effects of PTH are
mediated by its ionophoric property leading to increased entry of
calcium into skeletal muscle. A calcium channel blocker may, there-
fore, correct these derangements. The present study examined the
effects of verapamil on LCFA oxidation, CPT activity by skeletal
muscle mitochondria, and 45Ca uptake by skeletal muscle obtained from
CRF rats and normal animals treated with PTH with and without
verapamil. Both four days of PTH administration and 21 days of CRF
produced significant (P < 0.01) reduction in LCFA oxidation and CPT
activity of skeletal muscle mitochondria, and significant (P < 0.01)
increment in 45Ca uptake by skeletal muscle. Simultaneous treatment
with verapamil corrected all these derangements. Administration of
verapamil alone to normal rats did not cause a significant change in any
of these parameters. The data are consistent with the proposition that
the alterations in LCFA in CRF or after PTH treatment are related to
the ionophoric action of the hormone and could be reversed by a
calcium channel blocker.
Previous studies from our laboratory have demonstrated that
chronic renal failure (CRF) is associated with impaired oxida-
tion of long chain fatty acids (LCFA) by skeletal muscle [11.
This effect of CRF was due to reduced activity of carnitine
palmitoyl transferase (CPT) [1], an enzyme responsible for the
transfer of LCFA to the mitochondrial matrix for a-oxidation.
Additional studies have shown that this effect of CRF is
mediated by the associated state of secondary hyperparathy-
roidism, since parathyroidectomy in CRF animals prevented
the abnormalities in LCFA oxidation and CPT activity, and
PTH treatment of animals with normal renal function repro-
duced these derangements [1].
We have suggested that the effect of PTH on LCFA oxidation
and CPT activity of skeletal muscle could be due to an increase
in calcium uptake and Ion content of skeletal muscle [1] induced
by the calcium ionophoric effect of PTH [2—8]. It is possible,
therefore, that a calcium channel blocker may partially or
Received for publication April 12, 1988
and in revised form July 27, 1988
© 1988 by the International Society of Nephrology
totally prevent the PTH-induced calcium accumulation in skel-
etal muscle and may reverse the derangements in LCFA
oxidation in CRF.
The present study was undertaken to examine the effect of
the calcium channel blocker, verapamil, on 45Ca uptake by
skeletal muscle and CPT activity, and LCFA oxidation of
skeletal muscle mitochondria in animals treated with PTH and
in those with CRF.
Methods
Male Sprague-Dawley rats weighing 250 to 350 g were used in
the study. The animals were fed normal rat chow (Wayne
Research Animal Diets, Chicago, Illinois, USA) throughout the
study. The diet contained 1.4% calcium, 0.97% phosphorus,
and 4.4 IU/g of vitamin D. Previous studies in our laboratory
showed that a clear cut effect of PTH on mitochondrial oxygen
consumption occurred after four days of treatment with the
hormone [7]. Therefore, the present study utilized the four day
protocol of PTH treatment. The animals were housed in indi-
vidual cages.
The rats received an intraperitoneal injection of 200 U/day of
1-84 PTH (Sigma Chemical Company, St. Louis, Missouri,
USA) for four days. The hormone was dissolved in normal
saline, and half of the daily dose was given in the morning and
the other half in the late afternoon hours. The control animals
received sham injections containing the vehicle only. A third
group of animals were treated for four days with 1-84 PTH (200
U/day) and simultaneously received subcutaneous injections of
verapamil (Isoptene, Knoll, Ludwigschagen, Germany) in a
dose of 0.1 g/g body weight twice daily. A fourth group of rats
received verapamil only, for four days. Oxidation of a-ketoglu-
tarate, j3-hydroxybutyric acid (BHBA) and long chain fatty acid
(LCFA), and activity of CTP, of skeletal muscle mitochondria
and 45Ca uptake by skeletal muscle were examined on the
morning of day 5.
Studies were also performed after 21 days of CRF. The
animals underwent right partial nephrectomy, and a week later,
a left nephrectomy was performed. Some of the animals with
CRF received subcutaneous injections of verapamil (0.1 p.g/g
body wt twice daily) for the 21 days period of CRF. A third
group of normal rats received verapamil only for 21 days.
Studies of the oxidation of a-ketoglutarate, BHBA, and LCFA,
and CPT activity of skeletal muscle mitochondria, and 45Ca
uptake by skeletal muscle were done on the morning of day 22.
774
Perna et a!: Verapamil, renal failure, fatty acids oxidation 775
The animals were sacrificed by decapitation and the skeletal
muscle from the hind limb was removed and washed from
blood. The isolation of mitochondria was done according to the
method of Yang, Gieger and Bessman [9]. About 3 to 4 g of
muscle was placed in an ice-cold homogenization media con-
taining 180 mrt KC1, 10 mri EDTA disodium and the pH
adjusted to 7.4. The tissue was then cut into small pieces, run
through a Harvard Tissue press and treated for 15 minutes with
trypsin, and then homogenized with a Dounce type homoge-
nizer. A trypsin inhibitor was then added to stop the reaction.
The mixture was homogenized again and then diluted three-
folds with the homogenization media and centrifuged for 10
minutes, at 400 g, in a Sorvall RC-5 refrigerated centrifuge
(DuPont Co. Instrument Product Division, Newton, Connecti-
cut, USA). The pellet was discarded and the supernatant was
centrifuged at 8000 x g for 10 minutes, for final isolation of the
mitochondria. The mitochondrial pellet was washed several
times and suspended in a media containing 180 mri KC1, 10 mM
Tris HC1. After homogenization, the mixture was centrifuged at
8000 x g for 10 minutes and the pellet was suspended in 0.8 to
1.0 ml of a media containing 180 mri KC1, 10 mM Tris HC1 and
0.5% (wt/vol) dialyzed albumin. The pH of the media was 7.4.
The protein concentration of the mitochondrial pellet was
determined by a modification of the method of Lowry et al [10].
The isolated mitochondna were used for the study of the
oxidation of a-ketoglutarate, BHBA and LCFA and for the
activity of CPT. The respiratory control ratio and ADP:O ratio
were determined polarographically by means of a Clark oxygen
electrode (Gilson Medical Electronics, Middleton, Wisconsin,
USA), fitted to a plexiglass chamber of 2.0 ml capacity as
described originally by Chance and Williams [11]. The details
for the study of a-ketoglutarate oxidation have been previously
reported from our laboratory [7]. The complete system for the
oxidation of BHBA and LCFA contained between 1.0 to 1.5mg
mitochondrial protein added to 2 ml of incubation media con-
taining (in mM): 230 mannitol, 20 Tris HC1, 0.02 EDTA diso-
dium, 5 potassium phosphate, 70 sucrose and 11 malate. The
final pH was 7.2 and the temperature 28°C. About 1.0 to 1.5 mg
of mitochondnal protein contained in 120 p1 mitochondrial
solution and 50 p1 of 16 mrvi BHBA were added to the
incubation media in the oxygraph chamber giving a concentra-
tion of 0.4 mri BHBA. The studies for the evaluation of the
LCFA oxidation utilized activated fatty acid palmitoyl CoA
(Sigma Chemical Co.). To prepare this fatty acid for use in the
study, 1 mg of palmitoyl CoA was added to 1 ml of 100%
ethanol and sonicated for 10 to 15 minutes and then diluted with
4 ml of distilled water. The same oxygraph media was used as
that employed for the BHBA studies. About 1.0 to 1.5 mg
mitochondrial protein contained in 120 p1 of mitochondrial
solution, 50 p.l of 2 m of LD-carnitine and 50 p1 of 0.1 mM
palmitoyl CoA were added to the incubation chamber giving a
concentration of 0.05 m LD-carnitine and 0.0025 mrt palmi-
toyl CoA. Oxygen consumption was recorded and results were
calculated according to Chance and Williams [11] and ex-
pressed as nanomoles of oxygen per milligram of protein per
minute.
Activity of carnitine palmitoyl transferase was measured by
the method of Bieber, Abraham and Helmarth [12]. This
enzyme activity is determined by the release of free CoA in the
presence of exogenous L-carnitine, palmitoyl CoA and 5.5'-
dithiobis-(2 nitrobenzoate) (DTNB). The free CoA reduces
DTNB giving a yellow color which has a molar absorbance per
centimeter of 13.6 x io at 412 nm and at pH 8.0. To eliminate
the effect of endogenous mitochondrial L-carnitine, a parallel
assay is run with excess D-carnitine which inhibits the reaction
(blank); the activity of the enzyme is then calculated as the
difference between results observed in the presence of L- and
D-carnitine and expressed as nanomoles of CoA per milligram
protein per minute.
The uptake of 45Ca by the skeletal muscle was determined by
a modification of the method of Fleckenstein et al [13]. On the
day of the study, the animals received 20 Ci of 45Ca per kg
body weight intrapentoneally at 6 a.m. Six hours later the
animals were sacrificed by decapitation, blood was collected
and skeletal muscle samples were obtained and the wet weight
was determined. The muscle tissue was dissolved in soluene
X-l00 (Packard Instrument Corp., Downers Grove, Illinois,
USA); 1 ml of soluene was used per 1 mg wet weight. 45Ca in
blood and muscle samples was determined with a Beckman
liquid scintillation counter model L 5700 (Beckman Instrument,
Irvine California, USA). The skeletal uptake of 45Ca was
expressed as percentage uptake in 1 g wet tissue relative to the
counts in 100 ml of blood.
In all studies, blood samples were obtained for measurements
of calcium with atomic absorption spectrophotometer (Model
505, Perkin Elmer Corporation, Norwalk, Connecticut, USA)
and for inorganic phosphorus and creatinine with an autoana-
lyzer (Technicon Corp., Tarrytown, New York, USA). Data
are expressed as mean SE and statistical significance was
evaluated by parametric t-test.
Results
The results are presented in Table 1 and Figures 1 through 4.
There were no significant differences between the weight of
animals of the various groups and that of the normal rats at the
time of the study. There were no significant differences in the
plasma levels of calcium and creatinine between the normal rats
and those treated with PTH with and without verapamil, but
plasma phosphorus levels were significantly (P < 0.01) lower in
the PTH treated rats without verapamil than in normal rats and
in those treated with PTH and verapamil and with verapamil
alone. The nephrectomy procedure caused a significant rise in
the plasma levels of creatinine to values three to four times the
normal ones. There were no significant differences in the levels
of plasma creatinine between the CRF-control and CRF rats
treated with verapamil. The administration of the drug to
normal rats did not affect renal function. There was no signifi-
cant difference between the plasma levels of serum calcium and
phosphorus in the CRF rats with and without treatment with
verapamil and in the normal rats treated with the drug for 21
days.
The respiratory control ratio of the skeletal muscle mitochon-
dna in all groups of animals studies and for the various
substrates used, were within the range of intact mitochondria.
There were no significant differences in ADP:O ratios among
the various groups of rats.
Treatment with 1-84 PTH for four days caused significant
reductions in mitochondrial oxygen consumption with both
a-ketoglutarate (normal: 196 3.8 vs. 1-84 PTH: 152 3.0
nmol 02/mg protein/mm, P < 0.01; Fig. 1) and palmitoyl CoA
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Table 1. Effect of 1-84 PTH treatment and of chronic renal failure with or without verapamil, and of verapamil alone
Normal
4 Days 21 Days
PTH PTH-VER VER CRF CRF-VER VER
Weighting
Serum creatinine mg/dl
310 8.6
0.40 0.02
291 3.0
0.36 0.03
315 3.4
0.33 0.03
301 12.9
0.32 0.06
296 6.7
1.30 17b
302 8.6
1.54 017b
311 12.9
0.33 0.04
Serum calcium mg/dl 10.4 0.20 10.5 0.3 10.6 0.1 10.0 0.4 10.2 0.3 10.0 0.3 9.9 0.4
Serum phosphorus mg/dl 9.3 0.51 7.3 0.11" 8.6 0.68 8.7 0.37 8.3 0.36 8.0 0.50 8.3 0.35
a-ketoglutarate
RC ratio 13 0.9 11 1.2 12 1.2 12 1.2 10 0.80 11 0.9 12 0.8
ADP:O 3.0 0.08 2.9 0.06 2.8 0.04 2.9 0.3 3.0 0.06 2.8 0.12 3.0 0.08
3-hydroxybutyric acid
RC ratio 4.2 0.30 3.3 0.06 3.5 0.11 3.9 0.33 3.1 0.26 4.3 0.48 4.4 0.58
ADP:O 3.0 0.06 3.0 0.20 2.9 0.10 3.0 0.13 3.0 0.10 3.0 0.07 3.1 0.06
Palmitoyl CoA
RC ratio 6.5 0.74 3.7 0.21 4.4 0.42 5.5 0.53 5.4 0.69 6.1 0.46 6.1 0.07
ADP:O 3.0 0.07 2.7 0.11 2.7 0.09 2.8 0.05 2.9 0.09 2.9 0.04 3.0 0.07
45Ca uptake % 50 2.5 67 2.1 51 2.3 54 2.7 65 2.8a 55 3.0 53 2.1
Abbreviations are: RC, respiratory control; VER, verapamil. The number of animals in normal is 8, in PTH is 7, in PTH-VER is 7, in VER 4
days is 8, in CRF is 8, in CRF-VER is 6 and VER 4 days is 8.
a p < 0.01 compared to normal, to PTH-VER, to CRF-VER or to VER alone
"P < 0.01 compared to normal.
L-C FA BHBA
Fig. 1. Effects of administration of 1-84 PTH with and without treat-
ment of verapamil and of verapamil alone on oxidation of a-ketoglu-
tarate (a-KG), long chain fatty acid (LCFA) and -hydroxybutyric acid
(BHBA) by skeletal muscle mitochondria. Each column represents the
mean value and brackets denotes 1 SE. Symbols are: (U) normal; (U) 4
days PTH; () 4 days PTH and verapamil; (0) 4 days verapamil.
(normal: 62 1.3 vs. 1-84 PTH: 39 1.7 nmol!mg protein/mm,
P < 0.01; Fig. 1). Simultaneous treatment with verapamil
reversed these impairments and the values (a-ketoglutarate: 190
6.2, palmitoyl CoA: 61 3.6 nmol 02/mg protein/mm) were
not different from normals, Figure 1. Verapamil treatment alone
did not change mitochondrial oxygen consumption with a-
ketoglutarate (195 3.6 nmollmg protein/mm) or with palmitoyl
CoA (60 2.9 nmol/mg protein/mm). There were no significant
differences in mitochondrial oxygen consumption of BHBA
between normal rats, 1-84 PTH treated animals with or without
verapamil and animals treated with verapamil alone. Treatment
with 1-84 PTH also caused a significant impairment in CPT
activity (normal: 15,8 0.81 vs. PTH 1-84: 10.3 0.84 nmol
CoA/mg protein/mm, P <0.01; Fig. 2). Simultaneous treatment
with verapamil normalized the activity of this enzyme (14.9
0.61 nmol CoA/mg protein/mm) and verapamil alone had no
significant effect on CPT activity (14.6 0.24 nmol CoA!mg
protein/mm; Fig. 2).
Twenty-one days of CRF was associated with significant
reduction in mitochondrial oxygen consumption with both
a-ketoglutarate (normal: 196 3.8 vs. CRF: 161 3.8 nmollmg
protein/mm P <0.01) and palmitoyl CoA (normal: 62 1.3 vs.
40 2.0 nmol 02!mg protein/mm, P < 0.01; Fig. 3). CRF rats
treated with verapamil had mitochondrial oxygen consumption
within the normal range (cx-ketoglutarate: 193 4.5, palmitoyl
CoA: 61 2.8 nmol O2fmg protein/mm; Fig. 3), Treatment with
verapamil alone did not have a significant effect on mitochon-
drial oxygen consumption with a-ketoglutarate (191 5.1 nmoll
mg protein/mm) or with palmitoyl CoA (69 5.2 nmol/mg
protein/mm). CRF or treatment with verapamil did not produce
significant changes in BHBA oxidation.
The activity of CPT in CRF rats was significantly (P < 0.01)
lower than in normal animals (11.2 0.42 vs. 15.8 0.81 nmol
CoA!mg protein/mm; Fig. 4). Verapamil treatment of CRF rats
corrected this abnormality (16 1.03 nmol CoA/mg protein!
mm) and verapamil alone did not cause a significant change in
the activity of the enzyme (14.0 0.48 nmol/mg protein/mm).
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Fig. 2. Carnitine palmitoyl transferase activity of skeletal muscle
mitochondria from normal rats (U), animals treated with 1-84 PTH (U),
those treated simultaneously with PTH and verapamil (a), and rats
which received verapamil alone (0). Each column represents the mean
value and the brackets denotes 1 SE.
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Treatment for four days with PTH produced a significant (P
<0.01) increment in 45Ca uptake by skeletal muscle which was
corrected by the simultaneous administration of verapamil. The
subcutaneous injection of verapamil alone for four days did not
cause a significant change in 45Ca uptake by muscle. CRF was
also associated with a significant (P < 0.01) rise in skeletal
muscle 45Ca uptake. The administration of verapamil to CRF
rats prevented the increment in 45Ca uptake but did not affect it
in normal rats (Table 1).
Discussion
The results of the present study demonstrate that the simul-
taneous administration of verapamil to rats receiving PTH or
the treatment of CRF animals with verapamil normalized the
activity of CPT and corrected the abnormalities in LCFA and
a-ketoglutarate oxidation by skeletal muscle mitochondria.
We have previously suggested [1] that the derangement of
LCFA oxidation by skeletal muscle mitochondria produced by
PTH or CRF may be related to the calcium ionophoric action of
PTH [2—8]. Such an effect would result in increased and
possibly prolonged calcium uptake and/or content of skeletal
muscle which in turn may exert an adverse effect on mitochon-
drial function. Indeed, observations in the present study sup-
port such sequence of events. First, both PTH treatment of
normal animals and CRF in animals with intact parathyroid
glands caused significant increments in 45Ca uptake by the
skeletal muscle. Second, the treatment with the calcium chan-
nel blocker, verapamil, prevented the increased calcium uptake
by the skeletal muscle. Third, the derangement in CPT activity,
and mitochondrial oxidation of palmitoyl CoA and a-ketoglu-
tarate in PTH-treated rats and in CRF animals were observed
only when skeletal muscle 45Ca uptake was increased.
a-Ketoglutarate traverses the mitochondrial membrane uti-
lizing a ketoglutarate-malate carrier [14], and thereafter enters
the Krebs cycle. Therefore, the finding in our study, that
verapamil and the consequent prevention of calcium accumu-
lation in skeletal muscle also corrected a-ketoglutarate oxida-
tion by their mitochondria is consistent with the notion that
enhanced calcium uptake may affect the ketoglutarate-malate
carrier or the normal functioning of the Krebs cycle in the
mitochondrial matrix or both. Our studies do not differentiate
between these possibilities. It is interesting that neither the
administration of PTH nor CRF affected the oxidation of
BHBA. The mitochondrial oxidation of this substrate in normal
rats is low; it is possible, therefore, that a small effect of PTH or
CRF (10% or less) on the oxidation of BHBA is within the error
of the method and could not be detected.
Our suggestion on the effect of increased skeletal muscle
calcium on mitochondrial function may appear to be contradic-
tory to reports by other investigators [15—18]. It has been shown
that an acute increase in cytosolic calcium may enhance the
rates of oxidation of BHBA [15] and fatty acids [16], and may
stimulate the activity of pyruvate dehydrogenases [171 and
a-ketoglutarate dehydrogenases [18]. However, we would like
to propose that the difference between our results and those of
others may be related to the magnitude and duration of the
changes in cytosolic calcium. Such a proposition would imply
that a sustained and large increments in skeletal muscle calcium
may inhibit the function of skeletal muscle mitochondria. A
corollary to such a difference between an acute or a chronic
effect of changes in cytosolic calcium on organ function is found
in the observations on the action of PTH on the myocardium.
The hormone, by acutely raising calcium in the heart cells,
stimulates both their chronotropic [19] and inotropic [20] prop-
erties. In contrast, chronic exposure of the myocardium to
excess PTH produced marked increment in myocardial calcium
and was associated with impaired myocardial mitochondrial
function [21].
It is interesting to note that the adverse effects on mitochon-
drial function occurred only when a state of excess PTH was
present in addition to increased calcium uptake by the skeletal
muscle. This is similar to the in vitro observations of Bogin et al
[22], who demonstrated that neither PTH nor calcium alone
inhibited mitochondrial oxygen consumption, but the presence
of both PTH and calcium was required to cause such inhibition.
A large body of evidence exists indicating that skeletal
muscle is a target organ for PTH [7, 23, 24], and states of excess
PTH may be associated with muscle dysfunction [25—29]. In
two studies in addition to ours, the deleterious effects of PTH
was found to be due, at least in part, to its calcium ionophoric
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Fig. 3. Oxygen consumption by skeletal muscle mitochondria from
normal rats (a), animals with chronic renal failure (CRF, •), CRF rats
treated with verapamil (a), and normal animals given verapamil (El).
Each column represents mean value and brackets denotes 1 SE.
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Fig. 4. Carnitine palmitoyl transferase activity of skeletal muscle
mitochondria from normal rats (0), animals with chronic renal failure
(CRF, •), CRF rats treated with verapamil () and normal animals
given verapamil (El). Each column represents mean value and brackets
denotes 1 SE.
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action. Palmieri et a! [23] reported that reduction of calcium
influx by parathyroidectomy improved the muscular lesions of
hamster with muscle dystrophy. In addition, Baczynski et a! [7]
reported that in PTH-treated animals the skeletal muscle dis-
played increased 45Ca uptake and impaired energy production,
transfer and utilization; administration of verapamil corrected
all these abnormalities. Thus, these reports and our data
provide a potential rational approach for counterbalancing the
harmful effects of excess PTH on muscle function and metab-
olism. It should be mentioned, however, that in all these studies
verapamil was given from day one of the state of excess PTH.
It is not possible to predict, at the present time, what effect
verapamil may have if it is given after prolonged exposure to
excess PTH had already been present.
Our observations on a potential beneficial effect of verapamil
on the derangements of skeletal muscle metabolism in CRF is
another example of the therapeutic benefits of the calcium
channel blockers in the managements of other organs distur-
bances such hypertension, cardiac arrythmias, and ischemic
heart disease [301. These actions have also been attributed to
the blocking of calcium entry in the arterial wall or the myo-
cardium [31].
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